Worldwide Immunotherapy Drugs Market Outlook 2019-2025: Massive Growth Opportunities in Both Developed & Developing Regions - ResearchAndMarkets.com

DUBLIN--()--The "Global Immunotherapy Drugs Market - Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025" report has been added to ResearchAndMarkets.com's offering.

The global immunotherapy drugs market is expected to witness a CAGR of 12.5% to reach revenue of $215.6 billion by 2025.

The market has witnessed steady growth in the past few years, and the introduction of novel products has increased the acceptance of immunotherapy drugs in the market. The market is fueled by an upsurge in the incidence of lifestyle and chronic disease globally, reduction in disease recurrence, increasing product approval, and high preference for immunotherapy over traditional chemotherapy.

The growing market trend continues and is becoming one of the increasingly accepted treatments across many countries worldwide. The manufacturers are focusing on new approvals, collaboration, and development of new products due to the increase in demand for immunotherapy drugs for the treatment of cancer and other diseases.

Most of the revenue is generated from the leading players in the market with dominant sales such as AbbVie, Amgen, F. Hoffmann-La Roche, Bristol-Myers Squibb, Johnson & Johnson, and Merck & Co.

According to analysis, North America accounted for the largest share of the global immunotherapy drugs market in 2018. The US dominates the market owing to the presence of most of the immunotherapy drugs manufacturers in the region. Asia-Pacific is expected to grow at the fastest rate during the forecast period, owing to factors such as growing incidence of lifestyle diseases, increasing adoption of novel treatment, and low manufacturing cost.

By Drug Type

  • Monoclonal Antibodies (mAbs)
  • Vaccines
  • Non-specific Immunotherapies
  • Adaptive Cell Therapy
  • Others

The monoclonal antibodies segment occupied the largest share in 2018 and is expected to grow at low-double-digit CAGR during the forecast period. The adaptive cell therapy segment is expected to grow at a high CAGR during the forecast period 2019-2025.

By Treatment Area

  • Cancer
  • Inflammation and Autoimmune Disease
  • Infectious Disease
  • Others

In 2018, the cancer segment occupied the largest share and is expected to grow at a high CAGR during the forecast period due to the rising incidence of cancer globally and increasing preference for immunotherapy as a first line of treatment.

By Region

  • North America
  • Europe
  • APAC
  • RoW

North America is dominant in the global immunotherapy drugs market, followed by Europe and Asia Pacific. The significant share of the North America market comes from the US due to the availability of favorable reimbursement policies.

Competitive Analysis

The global immunotherapy drugs market has massive growth opportunities in both developed and developing regions. The introduction of a novel product with affordable drug cost is expected to increase the competition among the market players.

Many companies are currently focused on approvals, collaboration, and development of new products related to immunotherapy drugs due to increased demand for this therapy to treat various disease types.

For instance, in January 2019, BioNTech AG inked a deal with MAB Discovery GmbH to acquire MAB's operational antibody generation unit. The acquisition helps to expand BioNTech, which is a top privately-held developer of RNA-based therapeutics, further into monoclonal antibody (mAb) development to develop new treatments that combine technologies of both the companies.

In June 2018, Novartis received European approval for Aimovig, for the prevention of migraine in adults, and it works by blocking the activity of calcitonin gene-related peptide (CGRP) that is involved in migraine attacks. It is the only treatment specifically designed for migraine prevention to be approved in the European Union. In addition, other leading vendors are focusing on hugely investing in R&D activities to develop new products to obtain a high share in the market.

Key Vendors

  • AbbVie Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Merck & Co. Inc.

Competitive Facts

Increasing disease incidence, aging population, promising repayment or reimbursement plans in few nations, and enormous R&D activities for the immunotherapy drug development are the major factors driving the market growth.

With more than 8,000 ongoing trials for cancer immunotherapy, a huge amount of study concentrated on checkpoint inhibitors (CPi) and combinations with chemotherapies, targeted therapies, and other immune-oncology (IO) agents.

Benefits

The report provides complete details about the related sub-segments of the immunotherapy drugs market. Through this report, the key stakeholders can know about the major trends, drivers, investments, vertical player's initiatives, and government initiatives toward the disease management in the upcoming years along with details of the existing pure-play companies and new players entering the market.

Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.

Key Takeaways

  • Understanding the potential market opportunity with precise market size and forecast data.
  • A detailed market analysis focusing on the growth of the immunotherapy drugs industry.
  • Factors influencing the growth of the immunotherapy drugs market.
  • In-depth competitive analysis of dominant and pure-play vendors.
  • Prediction analysis of the immunotherapy drugs market in both developed and developing regions.
  • Key insights related to major segments of the immunotherapy drugs market.
  • Latest market trend analysis impacting the buying behavior of the consumers.

Topics Covered

1 Industry Outlook

1.1 Industry Overview

1.1.1 Global Driver for Pharmaceutical Demand

1.1.2 R&D Pipeline in Pharmaceutical Industry

1.1.3 Top Pharma Drugs by Sales (In $Million)

1.2 Industry Trends

2 Report Outline

2.1 Report Scope

2.2 Report Summary

2.3 Research Methodology

2.4 Report Assumptions

3 Market Snapshot

3.1 Market Definition

3.2 Benefits of Immunotherapy

3.3 Segmented Addressable Market (SAM)

3.4 Trends of the Immunotherapy Drugs Market

3.5 Related Markets

3.5.1 Human Insulin

3.5.2 Oncology Drugs

4 Market Outlook

4.1 List of Cancer Immunotherapy Drugs Approved (2016-April 2019)

4.2 Market segmentation

4.3 PEST Analysis

4.4 Porter 5 (Five) Forces

5 Market Characteristics

5.1 DRO - Global Immunotherapy Drugs Market Dynamics

5.1.1 Drivers

5.1.1.1 High Preference of Immunotherapy Over Traditional Chemotherapy

5.1.1.2 Growing Incidence of Lifestyle & Chronic Diseases

5.1.2 Opportunities

5.1.2.1 Emergence of Biosimilars

5.1.2.2 Increasing Opportunities in the Emerging Market

5.1.3 Restraints

5.1.3.1 High Immunotherapy Treatment Costs

5.1.3.2 Complex Manufacturing Process

5.2 DRO - Impact Analysis

5.3 Key Stakeholders

6 Drug Type: Market Size and Analysis

6.1 Overview

6.2 Monoclonal Antibodies (mAbs)

6.3 Vaccine

6.4 Non-specific Immunotherapy

6.5 Adaptive Cell Therapy

6.6 Others

7 Treatment Area: Market Size and Analysis

7.1 Overview

7.2 Cancer

7.3 Inflammatory and Autoimmune Diseases

7.4 Infectious Disease

7.5 Others

8 Regions: Market Size and Analysis

8.1 Overview

8.2 North America

8.3 Europe

8.4 Asia-Pacific

8.5 Rest of the World

9 Competitive Landscape

9.1 Overview

10 Vendor Profiles

10.1 AbbVie Inc.

10.1.1 Overview

10.1.2 Geographic Revenue

10.1.3 Business Focus

10.1.4 SWOT Analysis

10.1.5 Business Strategies

10.2 Amgen Inc.

10.3 F. Hoffmann-La Roche Ltd.

10.4 Bristol-Myers Squibb

10.5 Johnson & Johnson

10.6 Merck & Co. Inc.

11 Companies to Watch For

11.1 Novartis AG

11.2 GlaxoSmithKline PLC

11.3 AstraZeneca PLC

11.4 Eli Lilly & Company Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/ugto8o

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related Topics: Oncology Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related Topics: Oncology Drugs